Journal of Hematology & Oncology (Apr 2023)

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

  • Carolina Pavlovsky,
  • Bianca Vasconcelos Cordoba,
  • María Belén Sanchez,
  • Beatriz Moiraghi,
  • Ana Varela,
  • Rosario Custidiano,
  • Isolda Fernandez,
  • Maria Josefina Freitas,
  • Maria Verónica Ventriglia,
  • Georgina Bendek,
  • Romina Mariano,
  • María José Mela Osorio,
  • Miguel Angel Pavlovsky,
  • Ana García de Labanca,
  • Cecilia Foncuberta,
  • Isabel Giere,
  • Masiel Vera,
  • Mariana Juni,
  • Jose Mordoh,
  • Julio Cesar Sanchez Avalos,
  • Gerardo Cueto,
  • Silvia Miranda,
  • Estrella Mariel Levy,
  • Michele Bianchini

DOI
https://doi.org/10.1186/s13045-023-01440-6
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remission, and the prior time in deep molecular response (DMR) was associated with successful TFR. Luminex technology was used to characterize cytokines in plasma samples. Using machine learning algorithms, MCP-1 and IL-6 were identified as novel biomarkers and MCP-1low/IL-6low patients showed eightfold higher risk of relapse. These findings support the feasibility of TFR for patients in DMR and MCP-1/IL-6 plasma levels are strong predictive biomarkers.

Keywords